A metallopeptide targets and disrupts mitochondrial function in breast cancer stem cells – Science Daily
|
A metallopeptide targets and disrupts mitochondrial function in breast cancer stem cells
Science Daily Suntharalingam’s group recently proposed the organometallic compound copper(II) phenanthroline as a potent ROS generator with an especially deadly potential for cancer stem cells. However, this special agent must be delivered to its address and … |
The Guardian |
Leap forward towards gene therapy cure for haemophilia A
The Guardian One dose of a gene therapy given experimentally to 13 patients by NHS doctors in the UK has allowed them all to come off treatment. These were men – most sufferers are – who would not only bleed without stopping from an injury but would bleed into … Haemophilia A trial results ‘mind-blowing’BBC News |
Labiotech.eu |
Vertex licenses its first drug from CRISPR collaboration
BioPharma Dive Vertex Pharmaceuticals Inc. has selected CTX001 as the first drug it will co-develop and commercialize with CRISPR Therapeutics AG per the companies’ ongoing collaboration. Executives have already requested from regulators to conduct a Phase 1/2 trial … Vertex and CRISPR Therapeutics Partner on Gene Therapy for Blood DisordersBioPharm International Global CRISPR/Cas9 Tools Market Opportunity & Insights Report 2017Markets Insider Crispr Therapeutics (CRSP) vs. Immunomedics (IMMU) Critical AnalysisWeek Herald The Lincolnian Online all 12 news articles » |